CB1 receptors modulate affective behaviour induced by neuropathic pain

Brain Research Bulletin

Volumn 114, Issue , 2015, Pages 42-48

  Rácz, Ildikó ^a   Nent, Elisa ^a   Erxlebe, Edda ^a   Zimmer, Andreas ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Anxiety; CB1 receptor; Depression; Endocannabinoid system; Neuropathic pain; Partial sciatic nerve ligation

Indexed keywords

CANNABINOID 1 RECEPTOR; CNR1 PROTEIN, MOUSE; SUGAR INTAKE;

ANHEDONIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY DISORDER; ARTICLE; BEHAVIOR CHANGE; CONTROLLED STUDY; DEPRESSION; ELEVATED ZERO MAZE TEST; GENE DELETION; LIGHT-DARK TEST; MAZE TEST; MOOD CHANGE; MOUSE; NERVE LIGATION; NEUROPATHIC PAIN; NONHUMAN; PRIORITY JOURNAL; SCIATIC NERVE; SUCROSE PREFERENCE TEST; ADMINISTRATION AND DOSAGE; ANIMAL; ANIMAL HOUSING; ANXIETY; C57BL MOUSE; CHRONIC PAIN; DISEASE MODEL; GENETICS; HYPERALGESIA; KNOCKOUT MOUSE; METABOLISM; NEURALGIA; PATHOPHYSIOLOGY; PHENOTYPE; PHYSIOLOGY; PSYCHOLOGIC TEST; PSYCHOLOGY; PSYCHOMOTOR PERFORMANCE; SCIATIC NEUROPATHY; SUGAR INTAKE; TOUCH;

ANHEDONIA; ANIMALS; ANXIETY; CHRONIC PAIN; DEPRESSION; DIETARY SUCROSE; DISEASE MODELS, ANIMAL; HOUSING, ANIMAL; HYPERALGESIA; MICE, INBRED C57BL; MICE, KNOCKOUT; NEURALGIA; PHENOTYPE; PSYCHOLOGICAL TESTS; PSYCHOMOTOR PERFORMANCE; RECEPTOR, CANNABINOID, CB1; SCIATIC NEUROPATHY; TOUCH;

EID: 84927725634     PISSN: 03619230     EISSN: 18732747     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2015.03.005     Document Type: Article

References (58)

1. Assareh N., ElBatsh M.M., Marsden C.A., Kendall D.A. The effects of chronic administration of tranylcypromine and rimonabant on behaviour and protein expression in brain regions of the rat. Pharmacol. Biochem. Behav. 2012, 100:506-512. 10.1016/j.pbb.2011.10.017.
2. Attal N., Fermanian C., Fermanian J., Lanteri-Minet M., Alchaar H., Bouhassira D. Neuropathic pain: are there distinct subtypes depending on the aetiology or anatomical lesion?. Pain 2008, 138:343-353. 10.1016/j.pain.2008.01.006.
3. Azad S.C., Kurz J., Marsicano G., Lutz B., Zieglgänsberger W., Rammes G. Activation of CB1 specifically located on GABAergic interneurons inhibits LTD in the lateral amygdala. Learn. Mem. 2008, 15:143-152. 10.1101/lm.741908.
4. Beyer C.E., Dwyer J.M., Piesla M.J., Platt B.J., Shen R., Rahman Z., et al. Depression-like phenotype following chronic CB1 receptor antagonism. Neurobiol. Dis. 2010, 39:148-155. 10.1016/j.nbd.2010.03.020.
5. Caberlotto L., Rimondini R., Hansson A., Eriksson S., Heilig M. Corticotropin-releasing hormone (CRH) mRNA expression in rat central amygdala in cannabinoid tolerance and withdrawal: evidence for an allostatic shift?. Neuropsychopharmacology 2004, 29:15-22. 10.1038/sj.npp.1300296.
6. Castañé A., Célérier E., Martín M., Ledent C., Parmentier M., Maldonado R., et al. Development and expression of neuropathic pain in CB1 knockout mice. Neuropharmacology 2006, 50:111-122. 10.1016/j.neuropharm.2005.07.022.
7. Caulfield M.P., Brown D.A. Cannabinoid receptor agonists inhibit Ca current in NG108-15 neuroblastoma cells via a pertussis toxin-sensitive mechanism. Br. J. Pharmacol. 1992, 106:231-232.
8. Christensen R., Kristensen P.K., Bartels E.M., Bliddal H., Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 2007, 370:1706-1713. 10.1016/S0140-6736(07)61721-8.
9. Cravatt B.F., Lichtman A.H. The endogenous cannabinoid system and its role in nociceptive behavior. J. Neurobiol. 2004, 61:149-160. 10.1002/neu.20080.
10. Degroot A., Nomikos G.G. Genetic deletion and pharmacological blockade of CB1 receptors modulates anxiety in the shock-probe burying test. Eur. J. Neurosci. 2004, 20:1059-1064. 10.1111/j. 1460-9568.2004.03556.x.
11. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992, 258:1946-1949.
12. Freund T.F., Katona I., Piomelli D. Role of endogenous cannabinoids in synaptic signaling. Physiol. Rev. 2003, 83:1017-1066. 10.1152/physrev.00004.2003.
13. Griebel G., Stemmelin J., Scatton B. Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents. Biol. Psychiatry 2005, 57:261-267. 10.1016/j.biopsych.2004.10.032.
14. Haanpää M., Attal N., Backonja M., Baron R., Bennett M., Bouhassira D., et al. NeuPSIG guidelines on neuropathic pain assessment. Pain 2011, 152:14-27. 10.1016/j.pain.2010.07.031.
15. Haller J., Bakos N., Szirmay M., Ledent C., Freund T.F. The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety. Eur. J. Neurosci. 2002, 16:1395-1398.
16. Haller J., Varga B., Ledent C., Barna I., Freund T.F. Context-dependent effects of CB1 cannabinoid gene disruption on anxiety-like and social behaviour in mice. Eur. J. Neurosci. 2004, 19:1906-1912. 10.1111/j. 1460-9568.2004.03293.x.
17. Harvey A.G. Sleep and circadian rhythms in bipolar disorder: seeking synchrony, harmony, and regulation. Am. J. Psychiatry 2008, 165:820-829. 10.1176/appi.ajp.2008.08010098.
18. Hasnie F., Wallace V. Mechanical and cold hypersensitivity in nerve-injured C57BL/6J mice is not associated with fear-avoidance-and depression-related behaviour. Br. J. Anaesth. 2007, 98:816-822. 10.1093/bja/aem087.
19. Hill M., Gorzalka B. The endocannabinoid system and the treatment of mood and anxiety disorders. CNS Neurol. Disord. Drug Targets 2009, 8:451-458. 10.2174/187152709789824624.
20. Hill M.N., McLaughlin R.J., Pan B., Fitzgerald M.L., Roberts C.J., Lee T.T.-Y., et al. Recruitment of prefrontal cortical endocannabinoid signaling by glucocorticoids contributes to termination of the stress response. J. Neurosci. 2011, 31:10506-10515. 10.1523/JNEUROSCI. 0496-11.2011.
21. Jacob W., Yassouridis A., Marsicano G., Monory K., Lutz B., Wotjak C.T. Endocannabinoids render exploratory behaviour largely independent of the test aversiveness: role of glutamatergic transmission. Genes Brain Behav. 2009, 8:685-698. 10.1111/j.1601-183X.2009.00512.x.
22. Juhasz G., Chase D., Pegg E., Downey D., Toth Z.G., Stones K., et al. CNR1 gene is associated with high neuroticism and low agreeableness and interacts with recent negative life events to predict current depressive symptoms. Neuropsychopharmacology 2009, 34:2019-2027. 10.1038/npp.2009.19.
23. Kontinen V.K., Kauppila T., Paananen S., Pertovaara A., Kalso E. Behavioural measures of depression and anxiety in rats with spinal nerve ligation-induced neuropathy. Pain 1999, 80:341-346. 10.1016/S0304-3959(98)00230-9.
24. Kupferschmidt D.A., Newman A.E., Boonstra R., Erb S. Antagonism of cannabinoid 1 receptors reverses the anxiety-like behavior induced by central injections of corticotropin-releasing factor and cocaine withdrawal. Neuroscience 2012, 204:125-133. 10.1016/j.neuroscience.2011.07.022.
25. Lamont E.W., Legault-Coutu D., Cermakian N., Boivin D.B. The role of circadian clock genes in mental disorders. Dialogues Clin. Neurosci. 2007, 9:333-342.
26. Lamont E., Coutu D., Cermakian N., Boivin D. Circadian rhythms and clock genes in psychotic disorders. Isr. J. Psychiatry Relat. Sci. 2010, 27-35.
27. Landgraf D., McCarthy M.J., Welsh D.K. Circadian clock and stress interactions in the molecular biology of psychiatric disorders. Curr. Psychiatry Rep. 2014, 16:483. 10.1007/s11920-014-0483-7.
28. Lariviere W.R., Melzack R. The role of corticotropin-releasing factor in pain and analgesia. Pain 2000, 84:1-12.
29. Lee S., Kim D.H., Yoon S.-H., Ryu J.H. Sub-chronic administration of rimonabant causes loss of antidepressive activity and decreases doublecortin immunoreactivity in the mouse hippocampus. Neurosci. Lett. 2009, 467:111-116. 10.1016/j.neulet.2009.10.017.
30. Lutz B. Endocannabinoid signals in the control of emotion. Curr. Opin. Pharmacol. 2009, 9:46-52. 10.1016/j.coph.2008.12.001.
31. Maccarrone M., Valverde O., Barbaccia M.L., Castañé A., Maldonado R., Ledent C., et al. Age-related changes of anandamide metabolism in CB1 cannabinoid receptor knockout mice: correlation with behaviour. Eur. J. Neurosci. 2002, 15:1178-1186.
32. Maletic V., Raison C.L. Neurobiology of depression, fibromyalgia and neuropathic pain. Front. Biosci. (Landmark Ed.) 2009, 14:5291-5338.
33. Manzanares J., Urigüen L., Rubio G., Palomo T. Role of endocannabinoid system in mental diseases. Neurotox. Res. 2004, 6:213-224. 10.1007/BF03033223.
34. Martin M., Ledent C., Parmentier M., Maldonado R., Valverde O. Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology (Berl) 2002, 159:379-387. 10.1007/s00213-001-0946-5.
35. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990, 346:561-564. 10.1038/346561a0.
36. Matsuzawa-Yanagida K., Narita M., Nakajima M., Kuzumaki N., Niikura K., Nozaki H., et al. Usefulness of antidepressants for improving the neuropathic pain-like state and pain-induced anxiety through actions at different brain sites. Neuropsychopharmacology 2008, 33:1952-1965. 10.1038/sj.npp.1301590.
37. Mechoulam R., Ben-Shabat S., Hanus L., Ligumsky M., Kaminski N.E., Schatz A.R., et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 1995, 50:83-90.
38. Méndez-Díaz M., Caynas-Rojas S., Arteaga Santacruz V., Ruiz-Contreras A.E., Aguilar-Roblero R., Prospéro-García O. Entopeduncular nucleus endocannabinoid system modulates sleep-waking cycle and mood in rats. Pharmacol. Biochem. Behav. 2013, 107:29-35. 10.1016/j.pbb.2013.04.003.
39. Mika J., Zychowska M., Makuch W., Rojewska E., Przewlocka B. Neuronal and immunological basis of action of antidepressants in chronic pain - clinical and experimental studies. Pharmacol. Rep. 2013, 65:1611-1621.
40. Mikics E., Vas J., Aliczki M., Halasz J., Haller J. Interactions between the anxiogenic effects of CB1 gene disruption and 5-HT3 neurotransmission. Behav. Pharmacol. 2009, 20:265-272.
41. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993, 365:61-65. 10.1038/365061a0.
42. Patel S., Hillard C.J. Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling. J. Pharmacol. Exp. Ther. 2006, 318:304-311. 10.1124/jpet.106.101287.
43. Racz I., Nadal X., Alferink J., Baños J.E., Rehnelt J., Martín M., et al. Crucial role of CB(2) cannabinoid receptor in the regulation of central immune responses during neuropathic pain. J. Neurosci. 2008, 28:12125-12135. 10.1523/JNEUROSCI. 3400-08.2008.
44. Radat F., Margot-Duclot A., Attal N. Psychiatric co-morbidities in patients with chronic peripheral neuropathic pain: a multicentre cohort study. Eur. J. Pain 2013, 17:1547-1557. 10.1002/j. 1532-2149.2013.00334.x.
45. Rademacher D.J., Meier S.E., Shi L., Ho W.-S.V., Jarrahian A., Hillard C.J. Effects of acute and repeated restraint stress on endocannabinoid content in the amygdala, ventral striatum, and medial prefrontal cortex in mice. Neuropharmacology 2008, 54:108-116. 10.1016/j.neuropharm.2007.06.012.
46. Rodríguez de Fonseca F., Carrera M.R., Navarro M., Koob G.F., Weiss F. Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal. Science 1997, 276:2050-2054.
47. Romero-Sandoval E.A., Horvath R., Landry R.P., DeLeo J.A. Cannabinoid receptor type 2 activation induces a microglial anti-inflammatory phenotype and reduces migration via MKP induction and ERK dephosphorylation. Mol. Pain 2009, 5:25. 10.1186/1744-8069-5-25.
48. Rouwette T., Vanelderen P., Roubos E.W., Kozicz T., Vissers K. The amygdala, a relay station for switching on and off pain. Eur. J. Pain 2012, 16:782-792. 10.1002/j. 1532-2149.2011.00071.x.
49. Sindrup S.H., Otto M., Finnerup N.B., Jensen T.S. Antidepressants in the treatment of neuropathic pain. Basic Clin. Pharmacol. Toxicol. 2005, 96:399-409. 10.1111/j. 1742-7843.2005.pto_96696601.x.
50. Suzuki T., Amata M., Sakaue G., Nishimura S., Inoue T., Shibata M., et al. Experimental neuropathy in mice is associated with delayed behavioral changes related to anxiety and depression. Anesth. Analg. 2007, 104:1570-1577. table of contents. 10.1213/01.ane.0000261514.19946.66.
51. Treede R.-D., Jensen T.S., Campbell J.N., Cruccu G., Dostrovsky J.O., Griffin J.W., et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology 2008, 70:1630-1635. 10.1212/01.wnl.0000282763.29778.59.
52. Ulrich-Lai Y.M., Xie W., Meij J.T.A., Dolgas C.M., Yu L., Herman J.P. Limbic and HPA axis function in an animal model of chronic neuropathic pain. Physiol. Behav. 2006, 88:67-76. 10.1016/j.physbeh.2006.03.012.
53. Viveros M.P., Marco E.M., File S.E. Endocannabinoid system and stress and anxiety responses. Pharmacol. Biochem. Behav. 2005, 81:331-342. 10.1016/j.pbb.2005.01.029.
54. Wilson R.I., Nicoll R.A. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 2001, 410:588-592. 10.1038/35069076.
55. Yalcin I., Bohren Y., Waltisperger E., Sage-Ciocca D., Yin J.C., Freund-Mercier M.-J., et al. A time-dependent history of mood disorders in a murine model of neuropathic pain. Biol. Psychiatry 2011, 70:946-953. 10.1016/j.biopsych.2011.07.017.
56. Yalcin I., Barthas F., Barrot M. Emotional consequences of neuropathic pain: insight from preclinical studies. Neurosci. Biobehav. Rev. 2014, 47C:154-164. 10.1016/j.neubiorev.2014.08.002.
57. Zarrindast M.R., Mahboobi S., Sadat-Shirazi M.-S., Ahmadi S. Anxiolytic-like effect induced by the cannabinoid CB1 receptor agonist, arachydonilcyclopropylamide (ACPA), in the rat amygdala is mediated through the D1 and D2 dopaminergic systems. J. Psychopharmacol. 2011, 25:131-140. 10.1177/0269881110376688.
58. Zimmer A., Zimmer A.M., Hohmann A.G., Herkenham M., Bonner T.I. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:5780-5785.